To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report

Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e493-e496. doi: 10.1016/j.clml.2021.01.007. Epub 2021 Jan 13.

Authors

Roy Khalife¹, Andrew Aw², Lisa Duffett², Osman Radhwi², Lucie Lacasse², Lothar Huebsch², Mackenzie Bowman³, Paula James³, Alan Tinmouth²

Affiliations

¹ Department of Medicine (Hematology) and The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada. Electronic address: rkhalife@toh.ca.
² Department of Medicine (Hematology) and The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
³ Department of Medicine, Queen's University, Kingston, ON, Canada.

PMID: 33558201
DOI: 10.1016/j.clml.2021.01.007

No abstract available

Keywords: Hemorrhage; Leukemia; Lymphoma; von Willebrand Factor; von Willebrand diseases.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers
Blood Coagulation
Blood Coagulation Tests
Clinical Decision-Making
Disease Management
Disease Susceptibility
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
Male
Remission Induction
Symptom Assessment
Treatment Outcome
von Willebrand Diseases / diagnosis*
von Willebrand Diseases / etiology*
von Willebrand Diseases / therapy
von Willebrand Factor / therapeutic use

Substances

Biomarkers
von Willebrand Factor